Gains and losses of CD44 expression during breast carcinogenesis and tumour progression

Histopathology

Volumn 33, Issue 2, 1998, Pages 107-116

  Bankfalvi A ^a   Terpe, H J ^a   Breukelmann, D ^a   Bier, B ^b   Rempe, D ^a   Pschadka, G ^a   Krech, R ^c   Bocker W ^a,d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Department of Pathology   (Germany)

^c City Hospital   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Breast cancer prognosis; Breast carcinogenesis; CD44

Indexed keywords

HERMES ANTIGEN; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TUMOR GROWTH;

ANTIGENS, CD44; BREAST; BREAST DISEASES; BREAST NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE;

EID: 0031841536     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00472.x     Document Type: Article

References (44)

1. Haynes BF, Liao H-X, Patton KL. The transmembrane hyalurinate receptor (CD44): multiple functions, multiple forms. Cancer Cells 1991; 3; 347-350.
2. Ruiz P, Schwärzler C, Günther TU. CD44 isoforms during differentiation and development. BioEssays 1994; 17; 17-24.
3. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76; 301-314.
4. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrates. J. Cell Biol. 1992; 118; 971-977.
5. Günthert U, CD44: a multitude of isoforms with diverse functions. Curr Top. Microbiol. Immunol. 1993; 184; 47-63.
6. Günthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65; 13-24.
7. Seiter S, Arch R, Reber S et al. Prevention of tumour metastasis formation by anti-variant CD44. J. Evp. Med. 1995; 177; 443-455.
8. Wielega VJM, Heider KH, Offerhaus JA et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993; 53; 4754-4756.
9. Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 1995; 10; 2885-2899.
10. Terpe HJ, Störkel S, Zimmer U et al. Expression of CD44 isoforms in renal cell tumors: positive correlation to tumor progression. Am. J. Pathol 1996; 148; 453-463.
11. Fujita N, Yaegashi N, Ide Y et al. Expression of CD44 in normal versus tumor endometrial tissues: possible implications of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res. 1994; 54; 3922-3925.
12. Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett. 1995; 89; 81-87.
13. Salmi M, Grön-Virta K, Sointu P, Grenman R, Kalimo H, Jalkanen S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J. Cell Biol. 1993; 122; 431-442.
14. Piffkò J, Bankfalvi À, Klauke K et al. Unaltered strong immunohistochemical expression of CD44-v6 and -v5 isoforms during development and progression of oral squamous cell carcinomas. J. Oral Pathol. Med. 1996; 25; 502-506.
15. Günthert U, Stauder R, Mayer B, Terpe H-J, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv. 1995; 24; 19-41.
16. Zöller M, Kaufmann M. CD44 and metastasis. Onkologie 1994; 17; 114-122.
17. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J. Exp. Med. 1991; 174; 859-866.
18. Tanabe KK, Stamenkovic I, Culter BS, Takahashi K. Restoration of CD44 expression in colon carcinoma reduces tumorigenicity. Ann. Surg. 1995; 222; 493-503.
19. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 1997; 57; 846-849.
20. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am. J. Pathol. 1993; 143; 867-874.
21. Sinn HP, Heider KH, Skroch-Angel P et al. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res. Treat. 1995; 36; 307-313.
22. Friedrichs K, Franke F, Lisboa B-W et al. CD44 isoforms correlate with cellular differentiation hut not with prognosis in human breast cancer. Cancer Res. 1995; 55; 5424-5433.
23. Matsumara X, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992; 340; 1053-1058.
24. Hole AK, Belkhiri A, Snell LS, Watson PH. CD44 variant expression and estrogen receptor status in breast cancer. Breast Cancer Res. Treat. 1997; 43; 165-173.
25. Guriec N, Marcellin L, Gairard B et al. CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin. Exp. Metastasis 1996; 14; 434-439.
26. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta FH, Herrlic HP. CD44 variant exon epoitopes in primary breast cancer and length of survival. Lancet 1995; 345; 615-619.
27. Charpin C, Garcia S, Bouvier C et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum. Pathol. 1997; 28; 289-296.
28. Tempfer C, Losch A, Heinzl H et al. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur. J. Cancer 1996; 32A; 2023-2025.
29. Iida N, Bourguignon LY. Coexpression of CD44 variant (c10/ ex14) and CD44s in human mammary epithelial cells promotes tumorigenesis. J. Cell Physiol. 1997; 171; 152-160.
30. Sloane JP, Amendoeival I, Apostolikas N et al. Guidelines for pathology - supplement to European guidelines for quality assurance in mammography screening. Pathologe 1997; 18; 71-88.
31. Tavassoli FA. Intraductal hyperplasias, ordinary and atypical. In: Tavassoli FA, ed. Pathology of the Breast. New York: Appleton and Lange, 1992; 160-163, 171-184.
32. Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum. Pathol 1992; 23; 1095-1097.
33. Silverstein MJ, Poller Dn Waisman JR et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995; 345; 1154-1157.
34. Ellis IO, Elston CW. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991; 19; 403-410.
35. Bànkfalvi À, Navabi B, Bier B, Böcker W, Jasani B, Schmid KW. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J. Pathol. 1994; 174; 223-228.
36. Mackay CR, Terpe H-J, Stauder R, Marston WK, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J. Cell Biol. 1994; 124; 71-82.
37. Terpe HJ, Stark H, Prehrn P, Günthert U. CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 1994; 101; 79-89.
38. Böcker W, Bier B, Freytag G et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, α-smooth muscle actin, vimentin, collagen IV and laminin. I. Normal breast and benign proliferative lesions. Virchows Arch. 1992; 421; 315-322.
39. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J. Clin. Pathol. 1995; 48; 611-615.
40. Böcker W, Bier B, Freytag G et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, α-smooth muscle actin, vimentin, collagen IV and laminin. II. Epitheliosis and ductal carcinoma in situ. Virchows Arch. 1992; 421; 323-330.
41. Raju U, Crissman JD, Zarbo RJ, Gottlieb C. Epitheliosis of the breast. Am. J. Surg. Pathol. 1990; 14; 39-50.
42. Wetzels RHW, Holland R, Van Haelst UJGM, Lane EB, Leigh IM, Ra Maekers FCS. Detection of basement memrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am. J. Pathol 1991; 134; 571-579.
43. Bànkfalvi À, Öfner D, Schmid KW et al. Standardised in situ AgNOR analysis in breast pathology: Diagnostic and cell kinetic implications (submitted for publication).
44. Dall P, Heider KH, Sinn HP et al. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int. J. Cancer 1995; 60; 471-477.